TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

This study tests a new cell therapy called TC-D101 for people with relapsed or treatment-resistant small cell lung cancer (SCLC) whose tumors express a protein called DLL3. TC-D101 is a type of engineered immune cell designed to find and kill cancer cells that carry DLL3. **You may be eligible if...** - You are 18 to 75 years old - You have small cell lung cancer that has come back or stopped responding to treatment - Your tumor cells test positive for the DLL3 protein - You have not had success with or are not suitable for standard therapies - You have a life expectancy of at least 3 months and are in adequate general health **You may NOT be eligible if...** - Your tumor does not test positive for DLL3 - You have active or uncontrolled infections - You have had severe autoimmune disease or are on systemic immune-suppressing drugs - You have untreated brain metastases Talk to your doctor to see if this trial is right for you.